5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide | 501362-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide
• 英文别名: 4-iodomethyl-2-(3-methoxy-phenyl)-5-methyl-oxazol；4-iodomethyl-2-(3-methoxy-phenyl)-5-methyloxazole；2-(3-methoxyphenyl)-4-iodomethyl-5-methyloxazole；4-iodomethyl-2-(3-methoxyphenyl)-5-methyloxazole；4-(iodomethyl)-2-(3-methoxyphenyl)-5-methyl-1,3-oxazole
• CAS: 501362-93-2
• 化学式: C₁₂H₁₂INO₂
• 分子量: 329.137
• InChiKey: XJKVVHCZKAADFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide 、 cis-3-(benzyloxy)cyclohexanol 在 potassium tert-butylate 作用下， 以 氯苯 为溶剂， 反应 2.5h， 生成 (1S,3R)-4-(3-benzyloxy-cyclohexyl-1-oxymethyl)-2-(3-methoxyphenyl)-5-methyloxazole
  参考文献：
  名称：

  Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives

  摘要：

  描述了一种用于制备手性、非对映体、顺式配置的1,3-二取代环己醇衍生物的过程，其化学式为(I)，其中基团如所定义，通过酶促光学分辨的方法。

  公开号：

  US20040209931A1
• 作为产物：
  描述：

  4-(氯甲基)-2-(3-甲氧基苯)-5-甲基-1,3-恶唑 在 sodium iodide 作用下， 以 四氢呋喃 为溶剂， 生成 5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide
  参考文献：
  名称：

  Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives

  摘要：

  描述了一种用于制备手性、非对映体、顺式配置的1,3-二取代环己醇衍生物的过程，其化学式为(I)，其中基团如所定义，通过酶促光学分辨的方法。

  公开号：

  US20040209931A1

文献信息

• Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Glombik Heiner

  公开号：US06884812B2

  公开（公告）日：2005-04-26

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  本发明涉及二芳基环烷基衍生物及其生理上可接受的盐和生理功能衍生物。所述化合物包括具有以下式I的那些基团，其中所述基团如定义，以及其生理上可接受的盐和其制备方法。这些化合物通常具有降脂和/或三酸甘油酯降低作用，并且适用于治疗脂质代谢紊乱、II型糖尿病和X综合征等疾病。
• Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
  申请人：——

  公开号：US20030144332A1

  公开（公告）日：2003-07-31

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披萨店的员工们正在忙着准备今晚的外卖订单。
• Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209920A1

  公开（公告）日：2004-10-21

  Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

  芳基环烷基取代的烷基酸衍生物，其制备方法及其作为药物的用途。该发明涉及芳基环烷基取代的烷基酸衍生物及其生理可接受的盐和生理功能衍生物。所描述的化合物为式I，其中基团如所定义，以及其生理可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍、葡萄糖利用障碍以及胰岛素抵抗相关的疾病。
• Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040198786A1

  公开（公告）日：2004-10-07

  Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals The invention relates to cycloalkyl derivatives having bioisosteric carboxylic acid groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula 1, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  环烷基衍生物具有生物等效羧酸基团，其制备方法及其作为药物的用途。本发明涉及具有生物等效羧酸基团的环烷基衍生物及其生理上可接受的盐和生理功能衍生物。所描述的化合物具有下式1,1中所定义的基团，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用障碍以及胰岛素抵抗相关的紊乱。
• ARYLCYCLOAKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES
  申请人：Glombik Heiner

  公开号：US20070197605A1

  公开（公告）日：2007-08-23

  The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistence and the like comprising acetic acid derivatives with arylcycloalkyl-substituted alkanoic acid derivatives and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of the formula I wherein the various substituent R-groups are more specifically defined herein.

  本发明涉及用于治疗代谢紊乱的化合物和组合物，特别是用于治疗血液中的胰岛素相关代谢紊乱，如高脂血症、糖尿病、胰岛素抵抗等的乙酸衍生物和芳基环烷基取代的烷酸衍生物及其盐。被称为过氧化物酶体增殖物激活受体（PPAR）激动剂/拮抗剂，本发明涉及式I的化合物，其中各种取代基R组在此更具体地定义。